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Background. Based on what is known at this time, pregnant women are at an increased risk of severe illness from COVID-19
compared to nonpregnant women. Additionally, pregnant women with COVID-19 might have an increased risk of adverse
pregnancy outcomes. To investigate the effects of coronavirus disease 2019 (COVID-19) on mortality of pregnant and
postpartum women, we performed a systematic review of available published literature on pregnancies affected by COVID-19.
Methods. Web of Science, SCOPUS, and MEDLINE- databases were searched for original studies concerning the effect of
COVID-19 on mortality of pregnant and postpartum women published by July 10, 2020. Meta-analyses of proportions were
used to combine data and report pooled proportions. Results. 117 studies with a total of 11758 pregnant women were included.
The age ranged between 15 and 48 years. Most subjects were infected with SARS-CoV-2 in the third trimester. Disease severity
was not reported in 1125 subjects. Maternal mortality was 1.3%. In 100% of fatal cases with adequate data, fever alone or with
cough was one of the presenting symptoms. Also, dyspnea (58.3%) and myalgia (50%) were the most common symptoms. Sore
throat (8.3%) and gastrointestinal symptoms (anorexia, nausea) (8.3%) were rare. The rate of comorbidities was 20% among
COVID-19 deaths. The majority of COVID-19-infected women who died had cesarean section (58.3%), 25% had a vaginal
delivery, and 16.7% of patients were not full term. Conclusion. COVID-19 infection in pregnant women was associated with
higher rates (and pooled proportions) of cesarean section and mortality. Because new data are continuously being generated and
published, the findings of this study can be complete and updated with new researches. The results of this study can guide and
improve prenatal counseling of COVID-19-infected pregnant women.
1. Introduction
The coronavirus disease 2019 (COVID-19), caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is
a global public health crisis [1, 2]. The impact of COVID-
19 on specific populations, including pregnant women and
their newborns, remains mostly unknown and unstudied.
There is not sufficient information about the effect of this
disease in pregnant women, and most available studies
have evaluated the impact of the disease in the general
population. Pregnant women are at a higher risk for
acquiring viral respiratory infections and severe pneumo-
nia due to physiological changes in their immune and car-
diopulmonary systems [1–3].
The observed outcomes have been different from what
was seen during the H1N1 pandemic and with influenza
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outbreaks, all of which resulted in increased mortality in
women who were pregnant [4]. Studies in pregnant women
during coronavirus outbreaks (SARS-CoV) and Middle East
Respiratory Syndrome (MERS-CoV) show that pregnant
women are susceptible to experiencing adverse events such
as requiring hospitalization or intensive care unit (ICU)
admission, endotracheal intubation, and renal failure [5–7].
Worldwide, there are more than 140 million births every
year, and pregnant women are potentially at risk for adverse
outcomes of novel coronavirus. Although maternal mortality
has been reported in some studies, limited information is
available about SARS-CoV-2 infection in critically ill preg-
nant women hospitalized for COVID-19 [8, 9]. Also, there
is a multitude of case reports of infection with SARS-CoV-2
during pregnancy but their small sample size makes it
difficult to properly find potential complications [10, 11].
The findings of a study on 8207 SARS-CoV-2-infected
pregnant women showed an increased risk for ICU admis-
sion and mechanical ventilation compared with nonpregnant
women; however, the risk for death was similar [12]. Also,
the Centers for Disease Control and Prevention surveillance
report from the United States noted that pregnant women
were more likely to be admitted to the ICU and receive
mechanical ventilation than nonpregnant women. However,
after adjusting for age, presence of underlying medical
conditions, and race/ethnicity, mortality rate was not
increased [12].
Based on data from the early stage of pandemic, it is
reassuring that there are low rates of maternal mortality with
SARS-CoV-2 [13]. However, more studies are needed to
learn more about maternal mortality. This study is aimed at
performing a systematic review of available published litera-
ture on pregnancies affected by COVID-19 to evaluate the
effect of COVID-19 on mortality of pregnant and postpar-
tum women.
2. Methods
2.1. Study Design. This study is a systematic scoping review
based on the methodological framework of Arksey and
O’Malley [14]. Five stages of the framework they adopted
for conducting a scoping study are as follows: (1) identifying
the research question, (2) identifying relevant studies, (3)
study selection, (4) charting the data, and (5) collating,
summarizing, and reporting the results.
2.2. Research Questions. The main questions of the study
included the following. What is the mortality rate of
COVID-19 in pregnant and postpartum women, and how
many and what type of comorbidities were found in recov-
ered and deceased patients? What were the disease symptoms
and the mode of delivery in the maternal deaths?
2.3. Search Strategy and Eligibility Criteria. We searched sci-
entific databases of Web of Science, SCOPUS, and MED-
LINE through the interface, for original studies concerning
the effect of COVID-19 on maternal death published until
July 10, 2020. We designed a comprehensive optimal search
strategy consisted of two components related to pregnancy
and COVID-19. The complete search strategy is shown in
Table 1. Also, the Google Scholar engine was searched for
potentially relevant articles. Eligible studies for inclusion in
this systematic review were those that met all of the following
criteria: (i) the analysis was performed in pregnant and
postpartum women affected by COVID-19 (laboratory
confirmed and/or clinically diagnosed) and (ii) the study
was a full paper with original data and (iii) was written in
English. Studies were excluded if they did not provide suffi-
cient information about the patient outcome (survival or
death and important related details).
2.4. Study Selection. After removing the duplicates, the search
output was screened as the first step. The titles and abstracts
of the articles were screened by the two authors indepen-
dently according to the eligibility criteria. Then, in the sec-
ondary screening, the full texts of the retrieved articles were
reviewed by the same authors. Disagreements were resolved
through discussion and consensus.
2.5. Data Extraction. A data collection form was designed by
the authors to extract the data of the papers in an integrated
way. Characteristics of the studies were extracted, including
details of the first author’s name, country, sample size, age,
gestational age, comorbidities and complications in preg-
nancy, severity of COVID-19, ICU admission and ventilation
Table 1: Search strategy.
Pubmed
(Pregnancy [Title/Abstract] OR pregnan∗ [Title/Abstract] OR gestation∗ [Title/Abstract] OR conception [Title/Abstract]) AND (“Novel
coronavirus” [Title/Abstract] OR “Novel coronavirus 2019” [Title/Abstract] OR “2019 novel coronavirus” [Title/Abstract] OR “2019 nCoV”
[Title/Abstract] OR “Wuhan coronavirus” [Title/Abstract] OR “Wuhan pneumonia” [Title/Abstract] OR covid-19 [Title/Abstract] OR
“2019-nCoV” [Title/Abstract] OR “SARS-CoV-2” [Title/Abstract] OR “coronavirus 2019” [Title/Abstract] OR “2019-
nCoV”[Title/Abstract])
Web of Science
TOPIC: (pregnancy OR pregnan∗ OR gestation∗ OR conception) AND TOPIC: (“Novel coronavirus” OR “Novel coronavirus 2019” OR
“2019 novel coronavirus”OR “2019 nCoV”OR “Wuhan coronavirus”OR “Wuhan pneumonia”OR covid-19 OR “2019-nCoV”OR “SARS-
CoV-2” OR “coronavirus 2019” OR “2019-nCoV”)
SCOPUS
(TITLE-ABS-KEY (pregnancy OR pregnan∗ OR gestation∗ OR conception) AND TITLE-ABS-KEY (“Novel coronavirus” OR “Novel
coronavirus 2019” OR “2019 novel coronavirus” OR “2019 nCoV” OR “Wuhan coronavirus” OR “Wuhan pneumonia” OR covid-19 OR
“2019-nCoV” OR “SARS-CoV-2” OR “coronavirus 2019” OR “2019-nCoV”))
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need, complications during treatment of COVID-19, and
maternal mortality rate. In deceased patients, more informa-
tion was extracted, including presenting symptoms, mode of
delivery, duration of admission to death, and the result of the
polymerase chain reaction (PCR) testing of the neonates.
Data extraction was performed by two authors indepen-
dently, and any disagreements were resolved through discus-
sion and team consensus.
2.6. Statistical Analysis. All analyses were conducted by
STATA16 (StataCorp, College Station, Texas, USA). The
study statistician performed data extraction for primary
outcomes. Random effect meta-analyses were applied using
restricted maximum likelihood method [15]. The random
effect model was used because there may be other unknown,
unregistered/unpublished studies to which we could not have
access. The between-study heterogeneity was evaluated
using the Cochran Q test and Tau-squared, H-squared,
and I-squared statistics. Significance results of the test
and values higher than 75% for I-squared were considered
as substantial heterogeneity while a value of H-squared=1
indicates perfect homogeneity among the studies [16, 17].
The common effect sizes were calculated as the proportion
and rate for binary and count outcomes, respectively, and
their 95% confidence intervals (CIs). To assess the publica-
tion bias, the funnel plots were drawn. Additionally, Egger’s
[18] and Begg’s [19] tests were conducted. A nonparametric
“trim and fill” method of accounting for publication bias
was performed and showed that there is no need for a
modified effect size [20]. Finally, there were studies that
have just one sample in some outcomes that conducted a
sensitivity analysis by removing the studies with n = 1
sample.
2.7. Ethical Considerations. The present study complies with
all the recommended principles of research ethics. The offi-
cial approval of the Research Ethics Committee was not
obtained for this study because it was a review of the findings
of other previously published papers that were available to
the public. To comply with the ethical principles, the authors
did their best to avoid plagiarism and refused to manipulate
the data for personal interests. Respect for the rights of other
authors was provided by citing them in the text of the study
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synthesis
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3.1. Search Results. Figure 1 shows the PRISMA flow chart for
study selection. The search strategy retrieved 1348 records
and 4 additional records identified through Google Scholar
search. After removing 632 duplicates, 720 titles and
abstracts were screened. In the second screening, 167 full
texts were evaluated and a total of 117 studies were included
in the systematic review.
3.2. General Characteristics. The characteristics of the
included studies are shown in Table 2. A total of 11758 preg-
nant women entered the review study ranging from 1 to 8207
per study. The age range of patients was between 15 and 48
years. Most subjects were infected with SARS-CoV-2 in the
third trimester. Disease severity was not reported in 1125
samples. In the remaining cases, the highest frequency was
related to asymptomatic COVID-19 (n = 5466, 51.4%).
In terms of the country of origin, the highest frequencies
were in China with 34 articles [8, 12, 21–52], the United
States with 33 articles [5, 8, 12, 22–51], and Italy with 8 arti-
cles [52–59]. 65 studies including 10183 patients were under-
taken in the high-income countries [5, 8, 12, 22–83] and 52
studies (n = 1575) in middle-income countries [21, 84–134].
3.3. Outcomes
3.3.1. Mortality Rate of Pregnant and Postpartum Women
due to COVID-19. In total, there were 153 deaths out of
11758 pregnant and postpartum women affected by COVID-
19 (1.30%), of which 19 deceased patients were in high-
income countries including the United Kingdom, United States,
Italy, Switzerland, France, Sweden, Portugal, Netherlands,
Ireland, Spain, Canada, and Australia (mortality rate = 0:19%)
and 134 women were in middle-income countries including
China, Iran, Iraq, Jordan, Peru, Turkey, India, Venezuela, Thai-
land, Brazil, and Honduras (mortality rate = 8:51%).
The data on 136 cases of maternal death due to COVID-
19 is presented in Table 3. The highest mortality rate was
reported in the study of Takemoto et al. in Brazil using the
Brazilian Ministry of Health’s ARDS Surveillance System.
In this study, the authors found 124 deaths in COVID-19-
infected pregnant or postpartum women (12.7%) [131].
3.3.2. Presenting Symptoms of COVID-19 in Pregnant and
Postpartum Women Who Died of COVID-19. In all of the
fatal cases with adequate data, fever alone or with cough
was one of the presenting symptoms. After them, dyspnea
(58.3%) and myalgia (50%) were the most common symp-
toms, respectively. Sore throat (8.3%) and gastrointestinal
symptoms (anorexia, nausea) (8.3%) were rare.
3.3.3. Comorbidity Rate in Pregnant and Postpartum Women
Who Died of COVID-19. The comorbidity rate in women
who died from COVID-19 was 20% (Table 3). In total,
41.7% of the deceased patients were 35 years or older
(advanced maternal age), 31.1% had diabetes, 21.9% were
obese, 14.1% had cardiovascular disease (essential hyperten-
sion, gestational hypertension, preeclampsia, HELLP syn-
drome, and heart problems), and 9.1% had a history of
asthma.
3.3.4. Meta-Analysis Results for Morbidities in Patients Who







Heterogeneity: 𝜏2 = 0.24, I2 = 100.00%, H2 = 1.20e + 11
Test of 𝜃i = 𝜃j: Q (4) = 6.67e + 11, P = 0.00
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Figure 2: Forest plot of individual effect size for components and
all comorbidities.
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was 0.47 (95% CI: 0.04 to 0.90, P value = 0.03), for diabetes
was 0.29 (95% CI: -0.08 to 0.65, P value = 0.12), for asthma
was 0.41 (95% CI: -0.06 to 0.88, P value = 0.09), for cardio-
vascular disease was 0.03 (95% CI: -0.03 to 0.10, P value =
0.32), for advanced maternal age was 0.61 (95% CI: 0.13 to
1.08, P value = 0.01), and for all comorbidity rate was
14.02 (95% CI: -7.59 to 35.63, P value = 0.20), based on
a random effect model, with significant heterogeneity
between studies (I2 = 100:0% or about 100.0%, H2 > 1
and PQ < 0:001 for all effect sizes). Figure 2 shows the for-
est plot of individual effect sizes within each study. Assess-
ment for bias by Egger’s and Begg’s tests showed no
significant small-study effects (all P > 0:05). Further visual
inspection of the funnel plot suggested a slight degree of
publication bias (Figure 3).
3.3.5. Meta-Analysis Results for Obesity
(1) Obesity in All Pregnant and Postpartum Women Affected
by COVID-19. The proportion from 33 studies was 0.69 (95%
CI: 0.56 to 0.82, P value < 0.001) based on a random effect
model, with significant heterogeneity between studies (τ2 =
0:14, I2 = 100:0%, H2 = 1:28e + 11, Qðdf=32Þ = 9:68e + 11,
PQ < 0:001). Figure 4 shows the forest plot of individual
effect sizes within each study. Assessment for bias by Egger’s
and Begg’s tests showed no significant small-study effects
(P = 0:308 > 0:05 and P = 0:054 > 0:05, respectively). Further
visual inspection of the funnel plot suggests a slight degree of
publication bias (Figure 5).
(2) Sensitivity Analysis after Deleting the Studies with n=1.
Removing these studies resulted in an effect size Pr = 0:49
(95%CI: 0.33 to 0.66, P value < 0.001), with a significant hetero-
geneity (τ2 = 0:12, I2 = 100:0%, H2 = 8:72e + 10, Qðdf=17Þ =
1:07e + 07, PQ < 0:001). Figure 6 shows the forest plot of indi-
vidual effect sizes within each study.
(3) Subgroup Analysis of Obesity in Recovered and Dead
Pregnant and Postpartum Women. The forest plot of the
individual effect size of predetermined subgroup analysis by
dead/recovered is presented in Figure 7. The results indicate
higher proportion of outcome in the recovered subgroup
(Pr = 0:53, 95%CI = 0:36 to 0.71), than in the deceased sub-
group (Pr = 0:18, 95%CI = 0:11 to 0.25). Therefore, the test
showed a significant difference between the subgroups
(Qðdf=1Þ = 13:58, PQ < 0:001). Additionally, the heterogeneity
did not reduce in all subgroups (I2 = 93:65% and I2 = 100%
in the recovered and deceased subgroups, respectively).
Obesity Diabetes
Asthma Cardiovascular diseases
Advanced maternal age Comorbidities
0 .2 .4 .6 .8 1
Pr
Funnel plot Funnel plot
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Figure 3: Funnel plot of log relative risks vs. the standard error for components and all comorbidities.
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3.3.6. Meta-Analysis Results for Diabetes (Pregestational
or Gestational)
(1) Diabetes in All Pregnant and PostpartumWomen Affected
by COVID-19. The proportion from 38 studies was 0.38 (95%
CI: 0.25 to 0.51, P value < 0.001) based on a random effect
model, with significant heterogeneity between studies
(τ2 = 0:15, I2 = 100:0%, H2 = 4:62e + 10, Qðdf=37Þ = 5:95e + 7,
PQ < 0:001). Figure 8 shows the forest plot of individual effect
sizes within each study. Assessment for bias by Egger’s and
Begg’s tests showed no significant small-study effects
(P = 0:969 > 0:05 and P = 0:339 > 0:05, respectively). Further
visual inspection of the funnel plot suggested a slight degree
of publication bias (Figure 9).
(2) Sensitivity Analysis after Deleting the Studies with n=1.
Removing these studies resulted in an effect size Pr = 0:18













































































































Heterogeneity: 𝜏2 = 0.14, I2 = 100.00%, H2 = 1.28e + 11
Test of 𝜃i = 𝜃j: Q (32) = 9.68e + 11, P = 0.00
Test of 𝜃 = 0: z = 10.48, P = 0.00
Figure 4: Forest plot of individual effect size for obesity.

















Figure 5: Funnel plot of log relative risks vs. the standard error
for obesity.
18 Journal of Pregnancy
heterogeneity (τ2 = 0:04, I2 = 100:0%,H2 = 1:76 + 5,Qðdf=27Þ =
5:95e + 07, PQ < 0:001). Figure 10 shows the forest plot of
individual effect sizes within each study.
(3) Subgroup Analysis of Diabetes in Recovered and Dead
Pregnant and Postpartum Women. The forest plot of the
individual effect size of predetermined subgroup analysis by
dead/recovered is presented in Figure 11. The results indicate
lower proportion of outcome in the recovered subgroup
(Pr = 0:18, 95%CI = 0:10 to 0.25), than in the dead subgroup
(Pr = 0:18, 95%CI = 0:11 to 0.25), so that the test showed a
nonsignificant difference between the subgroups (Qðdf=1Þ =
0:37, PQ = 0:54 > 0:05). Additionally, the heterogeneity did
not reduce in all subgroups (I2 = 100:0% and I2 = 99:17% in
the recovered and dead subgroups, respectively).
3.3.7. Meta-Analysis Results for Cardiovascular Diseases
(1) Cardiovascular Diseases in All Pregnant and Postpartum
Women Affected by COVID-19. The proportion from 40
studies was 0.36 (95% CI: 0.24 to 0.48, P value < 0.001) based
on a random effect model, with significant heterogeneity
between studies (τ2 = 0:15, I2 = 100:0%, H2 = 3:52e + 10,
Qðdf=39Þ = 3:42e + 8, PQ < 0:001). Figure 12 shows the forest
plot of individual effect sizes within each study. Assessment
for bias by Egger’s and Begg’s tests showed no significant
small-study effects (P = 0:942 > 0:05 and P = 0:129 > 0:05,
respectively). Further visual inspection of the funnel plot sug-
gested a slight degree of publication bias (Figure 13).
(2) Sensitivity Analysis after Deleting the Studies with n=1.
Removing these studies resulted in an effect size Pr = 0:14
(95% CI: 0.10 to 0.18, P value < 0.001), with a significant het-
erogeneity (τ2 = 0:01, I2 = 100:0%, H2 = 2:15e + 4, Qðdf=29Þ =
2:57e + 04, PQ < 0:001). Figure 14 shows the forest plot of
individual effect sizes within each study.
(3) Subgroup Analysis of Cardiovascular Diseases in Recov-
ered and Dead Pregnant and Postpartum Women. The forest
plot of the individual effect size of predetermined subgroup
analysis by dead/recovered is presented in Figure 15. The
results indicate lower proportion of outcome in the recovered
subgroup (Pr = 0:14, 95%CI = 0:10 to 0.18), than in the
dead subgroup (Pr = 0:16, 95%CI = 0:16 to 0.17), so that
the test showed a nonsignificant difference between the





































































: Q (17) = 1.07e + 7, P = 0.00
Test of 𝜃 = 0: z = 5.91, P = 0.00
Figure 6: Forest plot of individual effect size for obesity after removing some studies.
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the heterogeneity did not reduce in all subgroup especially
(I2 = 100:0% and I2 =noncomputable in the recovered and
dead subgroups, respectively).
3.3.8. Mode of Delivery in Pregnant and Postpartum Women
Who Died of COVID-19. The mode of delivery in deceased
cases with sufficient data (n = 12) was as follows: 58.3% had
cesarean section, 25% had vaginal delivery, and 16.7% were
not full term. Meta-analysis for mode of delivery in the fatal
cases showed that the proportion from 6 studies was 0.00
(95% CI: -0.03 to 0.04, P value = 0.96) based on a random
effect model, with nonsignificant heterogeneity between
studies (τ2 = 0:00, I2 = 0:03%, H2 = 1, Qðdf=5Þ = 2:99, PQ =
0:70). Figure 16 shows the forest plot of individual effect sizes
within each study.
Assessment for bias by Egger’s and Begg’s tests showed
no significant small-study effects (P = 0:084 > 0:05 and P =
0:181 > 0:05, respectively). Further visual inspection of the
funnel plot suggested a slight degree of publication bias
(Figure 17).
3.3.9. Other Findings. Duration from admission to death was
between 2 and 22 days [85, 124]. The most common com-
plication during treatment of COVID-19 in pregnant and
postpartum women was acute respiratory distress syn-
drome (ARDS). In fatal cases, PCR testing of the neonate
was not indicated in 41.6% of cases (stillbirth, undeliv-
ered). In 41.6%, it was negative, and in 16.7% of the cases,
the result of the initial test was negative and the second
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Figure 7: Forest plot of individual effect size for obesity by subgroups.
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4. Discussion
In this study, we systematically investigated 117 published
reports involving 11758 pregnant women from the high- and
middle-income countries assessing the effect of COVID-19
on the risk of mortality.
In this systematic review, the mortality rate of COVID-19
in pregnant and postpartum women was 1.30% and the rate
of severe pneumonia was reported from 0 to 14%. The major-
ity of the patients were admitted to the ICU, and the maternal
death was consistent with reported outcomes from other
severe viral lower respiratory tract infections [5, 135–140].
Unlike the current study, in some studies, the mortality rate
of COVID-19-infected pregnant women was not higher than
nonpregnant women of reproductive age [13, 58, 141]. The
absence of deaths was explained by the younger age pregnant
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Figure 8: Forest plot of individual effect size for diabetes.

















Figure 9: Funnel plot of log relative risks vs. the standard error
for diabetes.
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mortality rate in COVID-19 patients is high in older individ-
uals and those patients with at least one comorbidity [127].
Also, the number of cases in these studies was relatively small
and all women were in their third trimester of pregnancy and
most of them gave birth earlier than seven days after diagno-
sis of the disease. Hence, this clinical manifestation-to-
delivery time may be too short to affect pregnancies [142].
Additionally, this discrepancy may be due to the data avail-
able at the time of publication in our study. The pregnancy-
related immunological changes may be one of the causes of
maternal vulnerability to COVID-19, but this did not signif-
icantly affect the response against SARS-CoV-2 [142]. In
addition, maternal mortality rates were lower in high-
income compared with low-income countries. In this sys-
tematic review, most of the studies were from China. It is
possible that our study reported a higher mortality rate than
other studies because our sample size was larger. Similar to
this finding, it was shown that the incidence of maternal
mortality rate in middle-income countries seems at least six
times higher than that in high-income countries [142]. These
findings indicate the weaknesses of maternity services in low-
income countries. In addition, major barriers for a more
equitable delivery of critical care in low-income countries
may be an important factor, such that in Brazil—a middle-
income country—only 72% of COVID-19-infected pregnant
or postpartum women with COVID-19 were admitted to the
ICU and 15% of them did not receive ventilation support
[131]. In Mexico, only two out of seven deaths had been
admitted to the ICU and received invasive respiratory
assistance [143].
Viral pneumonia is one of the leading causes of preg-
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Figure 10: Forest plot of individual effect size for obesity after removing some studies.
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in pregnant women are not different from others [144].
Maternal deaths due to cardiopulmonary complications,
sometimes with multiorgan failure, have been reported in
the previous literatures [9, 31, 102, 145]. In one study, preg-
nant women with SARS-CoV-2 infection in their second or
third trimester of pregnancy died due to cardiopulmonary
complications [9].
In all of the fatal cases, fever alone or with cough, dys-
pnea, and myalgia were the most common symptoms,
respectively. Sore throat and gastrointestinal symptoms were
rare. In accordance with this finding in another systematic
review, the most common symptoms at presentation were
fever, cough, dyspnea/shortness of breath, fatigue, and myal-
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Figure 11: Forest plot of individual effect size for obesity by subgroups.
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most common presenting symptoms of COVID-19 as
fever, cough, and dyspnea [147, 148]. In contrast with
our review, in some other systematic reviews, the symp-
toms were significantly different with fever and cough
occurring more than myalgia as well as dyspnea and
fatigue occurring only in approximately one-sixth of symp-
tomatic pregnant women [3, 149–153].
Another finding in this study was the high prevalence of
maternal comorbidities. The comorbidity rate in deceased
women was 20%, and most of the pregnant women show bio-
chemical evidence of inflammation, mainly lymphopenia.
However, in one study, nearly half of all patients (46%) had
no baseline comorbidities [31]. In another study, approxi-
mately one out of every three women with SARS-CoV-2
infection had a comorbid condition, but no maternal deaths
secondary to COVID-19 were reported [13]. High comorbid-
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Figure 12: Forest plot of individual effect size for CVD.

















Figure 13: Funnel plot of log relative risks vs. the standard error
for CVD.
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age of mothers. While similar to Khalil et al.’s study, maternal
mortality in our study was higher due to advanced maternal
age (35 years of age or older) [148] which makes manage-
ment of comorbidities challenging. Also, these comorbidities
per se could cause maternal deaths.
Advanced maternal age (age > 35) was the most prevalent
comorbidity; other comorbidities included diabetes, obesity,
cardiovascular disease (essential hypertension, gestational
hypertension, preeclampsia, HELLP syndrome, and heart
problems), and history of asthma, respectively. These comor-
bidities suggest that maternal morbidity is not different from
nonpregnant women of reproductive age. In one study,
obesity and pulmonary conditions such as asthma and
obstructive sleep apnea (OSA) were the most common
comorbidities. Also, maternal ICU admission was one of
the other outcomes. Also, pregnant and postpartum women
with COVID-19 admitted to the ICUs are at risk for maternal
death, which may occur even in the absence of substantial
baseline comorbidities [31, 148]. Another comorbidity was




































































































Heterogeneity: 𝜏2 = 0.01, I2 = 100.00%, H2 = 21471.96
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Figure 14: Forest plot of individual effect size for obesity after removing some studies.
25Journal of Pregnancy
not found in our study, the comorbidities could indirectly
lead to patients’ ICU admission and administration of
antiviral drugs. In contrast to our study, another study
showed none of the pregnant patients had preexisting
comorbidities, such as hypertension, cardiovascular dis-
ease, and asthma [9, 146].
Based on the results, the majority of deliveries in preg-
nant women with SARS COVID-19 were cesarean section.
Similar to this result, COVID-19 infection was associated
with a relatively higher cesarean delivery in other studies
[10, 31, 146]. Also, in another systematic review, the rate of
cesarean delivery was higher than in our study because more
than 90% of cesarean sections were from China (306/332).
Some articles from China have shown SARS-CoV-2 infection
as an indication for cesarean delivery [154–156], thereby jus-
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contrast to this finding, in Ferrazzi et al.’s study, 57% of
women delivered vaginally and elective cesarean sections
were performed in 43% of cases. Dyspnea or other COVID-
19-related symptoms resulted in 23.8% cesarean sections
among COVID-19-infected patients [157]. In the study by
Khalil et al., the rate of cesarean section in mothers with
COVID-19 was less than in our study. This difference can
be explained by the fact that in the study by Khalil et al.,
the rate of comorbidity was higher than our study (32.5%
vs. 20%), and this issue could be the reason for the cesarean
section rate reduction.
5. Limitation
There are no data available for the first and early second
trimester of pregnancy infections. Other limitation is the ret-
rospective design (especially reports and case series) of the
study. Also, we have only included studies which are reported
in the English language. The strengths of this study are large
number of studies, relatively high sample size, and the inclu-
sion of studies from different countries.
6. Conclusion
COVID-19 infection was associated with higher rates (and
pooled proportions) of cesarean section in pregnant women
and their mortality. Based on the results of this study,
COVID-19 cannot be considered as an indication for caesar-
ian delivery. Therefore, the timing and mode of delivery
should be individualized based on obstetrical indication and
maternal situation. The findings of this study can be a guide
to prenatal enhanced counseling for pregnant women with
COVID-19.
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